Free Trial

Day One Biopharmaceuticals (DAWN) News Today

$13.77
-0.10 (-0.72%)
(As of 05/24/2024 ET)
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by Franklin Resources Inc.
Franklin Resources Inc. boosted its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 4.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,236,795 shares of the company's stock after purchasing an ad
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Down 6.4%
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 6.4%
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $36,453.36 in Stock
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) insider Samuel C. Blackman sold 2,267 shares of the business's stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $16.08, for a total value of $36,453.36. Following the completion of the sale, the insider now directly owns 1,171,081 shares of the company's stock, valued at approximately $18,830,982.48. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Nicholas Investment Partners LP Sells 1,885,336 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Nicholas Investment Partners LP lessened its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 86.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 303,318 shares of the company's stock after selling 1,
Day One Biopharmaceuticals, Inc. Forecasted to Post Q2 2024 Earnings of ($0.75) Per Share (NASDAQ:DAWN)
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Stock analysts at Wedbush dropped their Q2 2024 earnings per share estimates for Day One Biopharmaceuticals in a research note issued on Tuesday, May 7th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings
FY2027 EPS Estimates for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Lowered by Analyst
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Analysts at Wedbush reduced their FY2027 earnings per share estimates for shares of Day One Biopharmaceuticals in a research report issued to clients and investors on Tuesday, May 7th. Wedbush analyst R. Driscoll now expects that the
TimesSquare Capital Management LLC Has $24.33 Million Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
TimesSquare Capital Management LLC raised its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 45.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,666,065 shares of the company's stock after
Day One Biopharmaceuticals (NASDAQ:DAWN) Given Outperform Rating at Wedbush
Wedbush reaffirmed an "outperform" rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday.
HC Wainwright Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $40.00
HC Wainwright decreased their target price on Day One Biopharmaceuticals from $50.00 to $40.00 and set a "buy" rating for the company in a research report on Tuesday.
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down on Insider Selling
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down After Insider Selling
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Sells $144,192.30 in Stock
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) CFO Charles N. York II sold 8,078 shares of Day One Biopharmaceuticals stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $17.85, for a total value of $144,192.30. Following the completion of the transaction, the chief financial officer now owns 217,293 shares of the company's stock, valued at $3,878,680.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 52-Week High at $17.87
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year High at $17.87
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading 5.2% Higher
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 5.2%
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 10.9%
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 10.9%
Day One Biopharmaceuticals' (DAWN) "Outperform" Rating Reiterated at Wedbush
Wedbush reissued an "outperform" rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday.
Day One Biopharmaceuticals (NASDAQ:DAWN) Sees Large Volume Increase Following Analyst Upgrade
Day One Biopharmaceuticals (NASDAQ:DAWN) Sees Large Volume Increase on Analyst Upgrade
Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Raised to $33.00 at Needham & Company LLC
Needham & Company LLC upped their target price on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday.
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 12.2% on Analyst Upgrade
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 12.2% After Analyst Upgrade
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up Following Analyst Upgrade
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up on Analyst Upgrade
Day One Biopharmaceuticals (NASDAQ:DAWN) PT Raised to $36.00 at JPMorgan Chase & Co.
JPMorgan Chase & Co. lifted their price objective on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an "overweight" rating in a research note on Monday.
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 4.7%
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Down 4.7%
Day One Biopharmaceuticals (NASDAQ:DAWN) Sees Strong Trading Volume
Day One Biopharmaceuticals (NASDAQ:DAWN) Sees Unusually-High Trading Volume
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading 3.8% Higher
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading 3.8% Higher
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Down 6.6% in March
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) was the target of a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 8,980,000 shares, a drop of 6.6% from the March 15th total of 9,610,000 shares. Currently, 15.2% of the company's stock are short sold. Based on an average daily trading volume, of 619,200 shares, the days-to-cover ratio is presently 14.5 days.
Vanguard Group Inc. Grows Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Vanguard Group Inc. grew its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 8.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,629,754 shares of the company's stock after buying an additional 34
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 3.4%
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Down 3.4%
Day One Biopharmaceuticals Inc DAWN
Get Day One Biopharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter.

Hooray! 97% OFF for the Memorial Day Sale (Ad)

Memorial Day Weekend Sale is Here - Get 97% OFF Sign up for StockEarnings Premium Membership and get complete access to Options Trade Alerts, Options Trade Ideas Software, advanced earnings screener, and downloadable Earnings Data for further analysis.

Memorial Day Weekend Sales Started. Click Here for Premium Membership.

DAWN Media Mentions By Week

DAWN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

DAWN
News Sentiment

0.19

0.76

Average
Medical
News Sentiment

DAWN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

DAWN Articles
This Week

7

2

DAWN Articles
Average Week

Get Day One Biopharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:DAWN) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners